Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells
- 1 September 1990
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 38 (3) , 333-339
- https://doi.org/10.1016/0090-8258(90)90068-v
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Therapeutic effect of recombinant human tumor necrosis factor in ovarian carcinoma xenograft in nude miceGynecologic Oncology, 1989
- In vitro analysis of the anticancer potential of tumor necrosis factor in combination with cisplatinGynecologic Oncology, 1989
- Intraperitoneal Lymphokine-Activated Killer Cell/Interleukin-2 Therapy in Patients With Intra- abdominal Cancer: Immunologic ConsiderationsJNCI Journal of the National Cancer Institute, 1989
- Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells.The Journal of Immunology, 1987
- Tumor necrosis factor induces synthesis of two proteins in human fibroblasts.Journal of Biological Chemistry, 1986
- Tumor necrosis factor receptors in HeLa cells and their regulation by interferon-gamma.Journal of Biological Chemistry, 1986
- Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferonNature, 1985
- Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.The Journal of Experimental Medicine, 1985